Cov khoom

Nqe lus piav qhia:
prim-o-glucosylcimifugin muaj lub zog tiv thaiv kab mob.Kev qhia ntawm iNOS thiab COX-2 tuaj yeem cuam tshuam los ntawm kev tswj hwm JAK2 / STAT3 teeb liab

Pawg muaj feem:
Kev taw qhia txoj hauv kev>> tiv thaiv kab mob thiab mob>> nitric oxide synthase
Kev tshawb fawb teb >> mob / tiv thaiv kab mob
Natural Products > > lwm yam

Hom phiaj:iNOS
COX-2

Kev tshawb fawb hauv Vitro:
prim-o-glucosylglycine (POG) yog cov ntsiab lus siab tshaj plaws ntawm chromone thiab ib qho ntawm cov khoom tseem ceeb hauv Fangfeng (RS).Prim-o-glucosylglycine plays lub luag haujlwm tiv thaiv kab mob hauv raw 264.7 macrophages los ntawm inhibiting JAK2 / STAT3 teeb liab hloov thiab inhibiting kev qhia ntawm iNOS thiab COX-2.Lub cytotoxicity ntawm prim-o-glucoside ntawm LPS tau txais raw 264.7 macrophages tau ntsuas.Siv LPS (1 μ G / ml) thiab nce cov concentration ntawm prim-o-glucosylglycine (15, 50 thiab 100 μ G / ml) rau 24 teev, thiab cell viability raug soj ntsuam los ntawm CCK-8 assay.Piv nrog DMSO kho hlwb (tswj), 24 teev thiab raug rau 15-100 μ Tom qab g / ml prim-o-glucoside, cell viability tsis cuam tshuam loj heev.Txhawm rau kawm txog cov tshuaj tiv thaiv kab mob ntawm prim-o-glucosylglycine, seb prim-o-glucosylglycine tuaj yeem cuam tshuam tsis muaj kev sib txuas tau raug tshuaj xyuas hauv LPS activated raw 264.7 hlwb.Siv LPS (1 μ G / ml) thiab ntau qhov ntau ntawm prim-o-glucosylglycine (15, 50 thiab 100 μ G / ml) rau 24 teev.Qhov concentration tsis tau ntsuas hauv kab lis kev cai supernatant los ntawm Griess cov tshuaj tiv thaiv.Qhov concentration ntawm tsis muaj nyob rau hauv kab lis kev cai supernatant nce ntau nrog LPS raug, thiab prim-o-glucoside ho inhibited LPS induced tsis muaj ntau lawm nyob rau hauv ib tug concentration nyob rau hauv [1].
Hauv Vivo Study
bronchoalveolar lavage kua (BALF) tau sau 7 teev tom qab lipopolysaccharide (LPS) kev tswj hwm, thiab qib cytokine hauv BALF tau ntsuas los ntawm ELISA.Piv nrog rau pawg tswj hwm, TNF hauv BALF- α, IL-1 β Thiab IL-6 qib nce ntxiv.Txawm li cas los xij, pretreatment nrog prime-o-glucosylglycine (2.5, 5 lossis 10 mg / kg) txo qis kev tswj hwm TNF- α, IL-1 β thiab IL-6 nyob rau hauv ib koob tshuaj (P <0.05, P < 0.05, 0.01). ) [1].

Kev sim ntawm tes
Cov khoom suav ntawm tes (CCK-8) tau siv los txiav txim siab cytotoxic concentration ntawm prim-o-glucosylglycine.Nyob rau hauv luv luv, raw 264.7 hlwb raug kho nrog 1 ib lub qhov dej × Qhov ceev ntawm 104 hlwb raug inoculated nyob rau hauv 96 lub qhov dej thiab incubated ib hmos.Tom qab ntawd siv 1 μ Cells tau txhawb nqa nrog g / ml LPS thiab kho nrog ntau qhov ntau ntawm prim-o-glucosylglycine (15, 50 thiab 100 μ g / mL; Medchem express, Princeton, NJ, USA) lossis DMSO kev kho mob.Tom qab incubation ntawm 37 ℃ rau 24 teev, CCK-8 tov tau ntxiv rau txhua lub qhov dej thiab incubated rau lwm teev.Absorbance tau ntsuas ntawm 450 nm siv tus nyeem ntawv microplate [1].

Kev sim tsiaj
nas [1] BALB / C txiv neej nas, 8 lub lis piam, hnyav txog 18 txog 20g.Cov nas tau muab faib ua 5 pawg: pawg tswj;pab pawg LPS;LPS + prime-o-glucosylglycine (2.5, 5 lossis 10mg / kg lub cev hnyav).Prime-o-glucosylglycine tau muab tshuaj rau hauv lub cev.Tom qab 1 teev, cov nas nyob hauv LPS pawg thiab LPS + prime-o-glucosylglycine pawg tau muab 50 mg / L intranasal (hauv) (200 mg / L) μ LLPs txhawm rau ua rau mob ntsws mob hnyav.Cov nas tswj tau muab 50% intranasal (hauv) yam tsis muaj LPS μ LPBS
[1]

Siv:
[1].Zhou J, et al.Prim-O-glucosylcimifugin Attenuates Lipopolysaccharideinduced Inflammatory Response hauv RAW 264.7 Macrophages.Pharmacogn Mag.2017 Jul-Sep; 13(51):378-384.
[2].Chen N, et al.Prime-O-glucosylcimifugin attenuates lipopolysaccharide-induced mob ntsws raug mob hauv cov nas.Int Immunopharmacol.Peb Hlis 2013; 16(2:139-47.